Skyepharma's asthma delivery system could be a $500m blockbuster
Monday 12 January 2009
There are countless companies that are no doubt glad to see the back of 2008, even if they are a little uncertain about what 2009 might bring. One of them is certainly the biotech group Skyepharma, whose annus horribilis last year saw its share price collapse under the weight of two convertible bonds worth £89m, on which investors had put options, exercisable this year and next.
The shares dropped from a year high of 744p to 116p, with some analysts predicting last year that had the bond investors so desired they could have forced the company out of business.
Indeed, last July, when the group's share price fell 32 per cent in one day – in pre-Lehman-collapse times, such falls were still considered astronomical – as talks between the company and its bondholders collapsed, the writing appeared to be on the wall.
So what a difference a few months makes. The group has always relied on its potential blockbuster asthma delivery system Flutiform, which was perhaps what saved the group from collapse, as investors recognised that Skyepharma was worth saving, and eventually renegotiated the terms of the deal by putting back the put dates on the bonds by several years.
Since the deal was struck, the news has got even better. Last week, a treatment called Lodotra, which treats arthritis and joint stiffness, was given approval to be used in Europe. The medicine uses Skyepharma's "Geoclock" technology, which ensures that the treatment takes effect at the necessary times.
While the group will not be able to suddenly pay back those troublesome bonds on the back of Lodotra's success – the company will receive a single-digit percentage royalty on net sales – it is at least a further step back from the precipice.
The group is desperately hoping that its filing for Food and Drug Administration approval for Flutiform, which is expected in before the end of March, is successful.
While the earnings from Geoclock will be welcomed, it is still Flutiform that excites analysts, with those at Piper Jaffray saying that the treatment could be worth as much as $500m (£328m).
- 1 Notting Hill Carnival: Woman shares selfie after being ‘punched in face for telling man to stop groping her’
- 2 Keira Knightley topless: Usually conservative actress does own take on #Freethenipple campaign for Interview Magazine
- 3 Daily Show's Jon Stewart destroys Fox News for its Ferguson coverage
- 4 When elitism grips the top of British society to this extent, there is only one answer: abolish private schools
- 5 Brother and sister, Christopher Buckner and Timothy Savoy, arrested for 'committing incest after watching 'The Notebook''
Ashya King missing: Police hunt five-year-old boy with brain tumour snatched from Southampton hospital by his parents
Keira Knightley topless: Usually conservative actress does own take on #Freethenipple campaign for Interview Magazine
YouTube video posted by Isis militants shows 'execution of 250 Syrian soldiers'
Botched ice bucket challenge leaves man critically injured after plane drops hundreds of gallons of water
Papua New Guinea Mount Tavurvur volcano eruption sees international flights diverted
Exclusive: We share blame for creating 'jihad generation', says Muslim strategist
Robin Williams Emmys tribute led by Billy Crystal criticised for including 'racist' joke about Muslim woman
The Rotherham child abuse scandal is a tale of apologists, misogyny and double standards
Scottish independence TV debate: Pumped-up Alex Salmond bounces back in bruising second round against Alistair Darling
Do you realise just how foolish the UK looks?
Ukip Douglas Carswell defection: Tory MP jumps ship to join Nigel Farage
- < Previous
- Next >
iJobs Money & Business
£50000 - £80000 per annum + benefits+bonus+package: Harrington Starr: Data Sci...
£450 - £500 per day: Orgtel: SAS Business Analyst, London, Banking, Credit Ris...
£32000 - £38000 Per Annum Bonus, Life Insurance + Other Benefits: Clearwater P...
£200 - £250 per day + competitive: Orgtel: KYC Analyst, Key Banking Client, Bi...